Reviva to Participate in the UBS Global Healthcare Conference
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on central nervous system, inflammatory and cardiometabolic diseases, has announced its participation in the UBS Global Healthcare Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat at the conference, which is scheduled for November 11-14, 2024, in Rancho Palos Verdes, CA. The presentation is specifically scheduled for Thursday, November 14, 2024, at 8:00 a.m. PT.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RVPH declined 3.03%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.
UBS Global Healthcare Conference
Format: Fireside chat
Date: Thursday, November 14, 2024
Time: 8:00 a.m. PT
Location: Rancho Palos Verdes, CA
Webcast Link: Click Here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com